Novo Nordisk A/S (NOV)
XDUS
Closed
Oct 6, 2026
Day's Range
32.8052 wk Range
30.26Overview - NOV - Novo Nordisk A/S
Key Statistics
Valuation
Enterprise Value
104.49B
P/E (Trailing)
‪1.44‬
PEG Ratio
‪-0.07‬
Price / Book
‪0.66‬
EV / EBITDA
‪0.69‬
Profitability
Gross Margin
‪78.21%‬
Profit Margin
‪80.97%‬
Operating Margin
‪43.59%‬
Return on Assets
‪18.86%‬
Return on Equity
‪52.78%‬
Ownership
Shares Outstanding
4.42B
Price stats
50-Day Avg
‪38.62‬
200-Day Avg
‪39.19‬
Dividends
Frequency
Semi-Annual
Peers - NOV - Novo Nordisk A/S
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on XDUS.
- NOVXDUSNovo Nordisk A/S-53.85%52-week change1.44P/E (Trailing)‪80.97%‬Profit Margin
- 6MKXDUSMerck & Co., Inc.+48.63%52-week change17.58P/E (Trailing)‪74.80%‬Profit Margin
- BAYAXDUSBayer AG Sponsored ADR+46.37%52-week change-13.48P/E (Trailing)‪58.75%‬Profit Margin
- IDPXDUSBiogen Inc.+41.07%52-week change22.50P/E (Trailing)‪75.69%‬Profit Margin
- BAYNXDUSBayer AG+36.72%52-week change-12.16P/E (Trailing)‪58.75%‬Profit Margin
- JNJXDUSJohnson & Johnson+34.83%52-week change21.25P/E (Trailing)‪67.87%‬Profit Margin
- JNJ0XDUSJohnson & Johnson CDR+32.21%52-week change19.22P/E (Trailing)‪67.87%‬Profit Margin
Profile Summary - NOV - Novo Nordisk A/S
About
Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
